IMPACT ON DRUG DEVELOPMENT

IMPACT ON DRUG DEVELOPMENT


The translational activities at the LSI of Dr. Cullis have resulted in the development of a series of new therapeutics. Dr. Cullis is an expert in the design of lipid nanoparticle (LNP) systems for the delivery of conventional small molecule drugs such as anticancer drugs as well as genetic drugs such as siRNA, antisense oligonucleotides and plasmids. In the case of small molecules LNP delivery leads to reduced toxicity and enhanced potency whereas LNP systems are required to enable the therapeutic potential of genetic drugs, which, in the free form, are readily broken down in the circulation, do not accumulate at sites of disease and cannot enter target cells.


 LSI_myocet

MARKET DRUGS

Three drugs originating from the Cullis Lab have made it into the market:

 

Drug Trade Name Indication Status (2007) Company
LNP Amphotericin ABELCET Fungal infections Approved US,
Europe 1995
Enzon
LNP Doxorubicin Myocet Metastatic Breast Cancer Approved Europe,
Canada 2000
Cephalon
LNP Vincristine Marqibo Acute lymphocytic
leukemia
Approved US
2012
Spectrum

A series of LNP based drugs for breast, lung and liver cancer and cystic fibrosis from the Cullis Lab are also at varying levels of clinical development that could be on the market in the next 5 years.